187 related articles for article (PubMed ID: 25344985)
21. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
22. Multiple biomarker panels for early detection of ovarian cancer.
Yurkovetsky ZR; Linkov FY; E Malehorn D; Lokshin AE
Future Oncol; 2006 Dec; 2(6):733-41. PubMed ID: 17155900
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer screening: a look at the evidence.
Fields MM; Chevlen E
Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
[TBL] [Abstract][Full Text] [Related]
24. New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening.
Chan A; Gilks B; Kwon J; Tinker AV
Obstet Gynecol; 2012 Oct; 120(4):935-40. PubMed ID: 22996112
[TBL] [Abstract][Full Text] [Related]
25. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
26. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
27. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
28. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer.
Gogoi R; Srinivasan S; Fishman DA
Expert Rev Mol Diagn; 2006 Jul; 6(4):627-37. PubMed ID: 16824035
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
30. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
31. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer.
Kim YW; Bae SM; Kim IW; Liu HB; Bang HJ; Chaturvedi PK; Battogtokh G; Lim H; Ahn WS
Oncol Rep; 2012 Aug; 28(2):585-91. PubMed ID: 22641176
[TBL] [Abstract][Full Text] [Related]
32. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
33. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B
Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for early detection of ovarian cancer.
Nguyen L; Cardenas-Goicoechea SJ; Gordon P; Curtin C; Momeni M; Chuang L; Fishman D
Womens Health (Lond); 2013 Mar; 9(2):171-85; quiz 186-7. PubMed ID: 23477323
[TBL] [Abstract][Full Text] [Related]
35. New technologies for the identification of markers for early detection of ovarian cancer.
Bandera CA; Ye B; Mok SC
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):51-5. PubMed ID: 12544502
[TBL] [Abstract][Full Text] [Related]
36. Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.
Nawaz M; Fatima F; Nazarenko I; Ekström K; Murtaza I; Anees M; Sultan A; Neder L; Camussi G; Valadi H; Squire JA; Kislinger T
Expert Rev Proteomics; 2016; 13(4):395-409. PubMed ID: 26973172
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer molecular pathology.
Longuespée R; Boyon C; Desmons A; Vinatier D; Leblanc E; Farré I; Wisztorski M; Ly K; D'Anjou F; Day R; Fournier I; Salzet M
Cancer Metastasis Rev; 2012 Dec; 31(3-4):713-32. PubMed ID: 22729278
[TBL] [Abstract][Full Text] [Related]
38. Biomarker testing for ovarian cancer: clinical utility of multiplex assays.
Nolen BM; Lokshin AE
Mol Diagn Ther; 2013 Jun; 17(3):139-46. PubMed ID: 23552992
[TBL] [Abstract][Full Text] [Related]
39. Clinical potential of proteomics in the diagnosis of ovarian cancer.
Ardekani AM; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2002 Jul; 2(4):312-20. PubMed ID: 12138495
[TBL] [Abstract][Full Text] [Related]
40. Proteomics success story. Towards early detection of breast and ovarian cancer: plasma proteomics as a tool to find novel markers.
Souchelnytskyi S; Lomnytska M; Dubrovska A; Hellman U; Volodko N
Proteomics; 2006 Sep; 6 Suppl 2():65-8. PubMed ID: 17031801
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
